A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01455532
First received: October 7, 2011
Last updated: September 14, 2013
Last verified: September 2013
  Purpose

Primary Objective:

  • To assess the safety and the maximum tolerated dose(MTD) of iniparib as a single agent and in combination with chemotherapeutic regimens in patients with advanced solid tumors that are refractory to standard therapy.

Secondary Objectives:

  • To assess the antitumor effect of iniparib (per Response Evaluation Criteria in Solid Tumors [RECIST]) Version 1.1 in patients with measurable disease.
  • To characterize iniparib (and its metabolites, if possible) pharmacokinetics.

Based on data generated by Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.


Condition Intervention Phase
Neoplasm Malignant
Drug: Iniparib (SAR240550-BSI-201)
Drug: Gemcitabine
Drug: Carboplatin
Drug: Placlitaxel
Drug: Pegylated liposomal doxorubicin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Assessment of iniparib as single agent and in combination with chemotherapeutic agents related dose limiting toxicities (DLTs) observed at first cycle [ Time Frame: 3 - 4 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To assess the antitumor effect of iniparib according to the Response Evaluation Criteria in Solid Tumors [RECIST]) Version 1.1 in patients with measurable disease [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  • Pharmakokinetic (PK) parameters: Cmax [ Time Frame: 0, 0.5, 1, 1.33, 1.67, 2, 4, 5, 7 and 10 h post dose ] [ Designated as safety issue: No ]
  • Pharmakokinetic (PK) parameters : tmax [ Time Frame: 0, 0.5, 1, 1.33, 1.67, 2, 4, 5, 7 and 10 h post dose ] [ Designated as safety issue: No ]
  • Pharmakokinetic (PK) parameters: tlast [ Time Frame: 0, 0.5, 1, 1.33, 1.67, 2, 4, 5, 7 and 10 h post dose ] [ Designated as safety issue: No ]
  • Pharmakokinetic (PK) parameters: AUC [ Time Frame: 0, 0.5, 1, 1.33, 1.67, 2, 4, 5, 7 and 10 h post dose ] [ Designated as safety issue: No ]
  • Pharmakokinetic (PK) parameters : t1/2z [ Time Frame: 0, 0.5, 1, 1.33, 1.67, 2, 4, 5, 7 and 10 h post dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 160
Study Start Date: November 2011
Estimated Study Completion Date: February 2014
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Iniparib, single agent
Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
Drug: Iniparib (SAR240550-BSI-201)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Experimental: Iniparib/Gemcitibine/Carboplatin
Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
Drug: Iniparib (SAR240550-BSI-201)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: Gemcitabine

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: Carboplatin

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Experimental: Iniparib/Paclitaxel
Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
Drug: Iniparib (SAR240550-BSI-201)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: Placlitaxel

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Experimental: Iniparib/Pegylated liposomal doxorubicin/Carboplatin
Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
Drug: Iniparib (SAR240550-BSI-201)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: Carboplatin

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: Pegylated liposomal doxorubicin

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous


Detailed Description:

The duration of the study for an individual patient will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (3 weeks or 4 weeks depending on regimen) of study treatment, and an end-of-treatment visit at least 30 days following the last administration of study drug. However, treatment may continue until precluded by toxicity, progression, or death.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Capable of understanding and complying with the protocol requirements, and have signed the informed consent document
  • ≥18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • To have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease; that is refractory to standard therapy and/or therapies known to provide clinical benefit or for which no standard therapy exists
  • For phase 1b, patients for whom the backbone chemotherapy (dose and schedule) can be considered as a standard therapeutic regime for their cancer.
  • Have measurable disease or non-measurable disease, defined according to RECIST Version 1.1. Patients with skin only metastases are eligible, if the appropriate photography documentation (including measurement) of the skin metastases is provided.
  • Adequate organ and bone marrow function
  • Willingness, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ an effective barrier method of contraception during the study drug administration and for a period of 6 months following the last dose.
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment, and at least 6 months after the last dose of study treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose. If a female partner becomes pregnant during course of study the treating physician should be informed immediately.

Exclusion criteria:

  • Systemic anticancer therapy within 14 days before the first dose of study drug.
  • Known allergy or hypersensitivity to components of the iniparib, gemcitabine, paclitaxel, PLD,or carboplatin formulation.
  • Not recovered to Grade ≤1 from adverse events (AE), per NCI-CTCAE Version 4.03 or to within 10% of pre-treatment baseline values, due to investigational drugs, radiation, or other medications administered more than 30 days before enrollment in this study. Alopecia at screening is not exclusionary.
  • Prior radical (curative) radiation therapy for treatment of cancer ≥25% of the bone marrow (1). Prior radiation to the whole pelvis is not allowed. Prior radical radiotherapy must be completed at least 4 weeks before study entry.
  • Patients who have received palliative radiation therapy for symptomatic metastases must have completed treatment ≥14 days prior to initiation of study treatment.
  • Active brain metastases. Patients with treated brain metastases are eligible, if 1. Radiation therapy was completed at least 2 weeks prior to study treatment; 2. Follow-up scan shows no disease progression; and 3. Patient does not require steroids. Screening for brain metastases is not required if the patient is asymptomatic.
  • Clinically significant cardiac disease including congestive heart failure (New York Heart Association Class III or IV), including pre-existing ventricular arrhythmia or conduction abnormality requiring medication, or cardiomyopathy or history of a myocardial infarction within the last 6 months
  • Other major medical condition (eg, uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection) which the Investigator feels might compromise the patient's effective and safe participation in the trial.
  • Pregnant or breastfeeding
  • Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or Hepatitis C Antibodies (HCAb). Testing is not required unless circumstances warrant confirmation.
  • Patients with acute or chronic leukemia or with any other disease likely to have a significant bone marrow infiltration (screening not required).
  • Prior treatment with gemcitabine, carboplatin, paclitaxel, or Pegylated liposomal doxorubicin.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01455532

Locations
United States, Arizona
Investigational Site Number 840002
Scottsdale, Arizona, United States, 85258
United States, California
Investigational Site Number 840004
Los Angeles, California, United States, 90048
United States, Georgia
Investigational Site Number 840010
Augusta, Georgia, United States, 30912
United States, Missouri
Investigational Site Number 840007
St Louis, Missouri, United States, 63110
United States, Ohio
Investigational Site Number 840001
Cincinnati, Ohio, United States, 45267-0542
United States, Texas
Investigational Site Number 840006
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01455532     History of Changes
Other Study ID Numbers: TED11746, U1111-1118-6091
Study First Received: October 7, 2011
Last Updated: September 14, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms
Doxorubicin
Liposomal doxorubicin
Gemcitabine
Carboplatin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on August 28, 2014